Favorable Changes in Biomarkers of Potential Harm to Reduce the Adverse Health Effects of Smoking in Smokers Switching to the Menthol Tobacco Heating System 2.2 for 3 Months (Part 2)
Abstract Introduction Tobacco Heating System (THS) 2.2, a candidate modified-risk tobacco product, aims at offering an alternative to cigarettes for smokers while substantially reducing the exposure to harmful and potentially harmful constituents found in cigarette smoke. Methods One hundred and six...
Gespeichert in:
| Veröffentlicht in: | Nicotine & tobacco research 2020-04, Vol.22 (4), p.549-559 |
|---|---|
| Hauptverfasser: | , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 559 |
|---|---|
| container_issue | 4 |
| container_start_page | 549 |
| container_title | Nicotine & tobacco research |
| container_volume | 22 |
| creator | Haziza, Christelle de La Bourdonnaye, Guillaume Donelli, Andrea Skiada, Dimitra Poux, Valerie Weitkunat, Rolf Baker, Gizelle Picavet, Patrick Lüdicke, Frank |
| description | Abstract
Introduction
Tobacco Heating System (THS) 2.2, a candidate modified-risk tobacco product, aims at offering an alternative to cigarettes for smokers while substantially reducing the exposure to harmful and potentially harmful constituents found in cigarette smoke.
Methods
One hundred and sixty healthy adult US smokers participated in this randomized, three-arm parallel group, controlled clinical study. Subjects were randomized in a 2:1:1 ratio to menthol Tobacco Heating System 2.2 (mTHS), menthol cigarette, or smoking abstinence for 5 days in confinement and 86 subsequent ambulatory days. Endpoints included biomarkers of exposure to harmful and potentially harmful constituents (reported in our co-publication, Part 1) and biomarkers of potential harm (BOPH).
Results
Compliance (protocol and allocated product exposure) was 51% and 18% in the mTHS and smoking abstinence arms, respectively, on day 90. Nonetheless, favorable changes in BOPHs of lipid metabolism (total cholesterol and high- and low-density cholesterol), endothelial dysfunction (soluble intercellular adhesion molecule-1), oxidative stress (8-epi-prostaglandin F2α), and cardiovascular risk factors (eg, high-sensitivity C-reactive protein) were observed in the mTHS group. Favorable effects in other BOPHs, including ones related to platelet activation (11-dehydrothromboxane B2) and metabolic syndrome (glucose), were more pronounced in normal weight subjects.
Conclusions
The results suggest that the reduced exposure demonstrated when switching to mTHS is associated with overall improvements in BOPHs, which are indicative of pathomechanistic pathways underlying the development of smoking-related diseases, with some stronger effects in normal weight subjects.
Implications
Switching to mTHS was associated with favorable changes for some BOPHs indicative of biological pathway alterations (eg, oxidative stress and endothelial dysfunction). The results suggest that switching to mTHS has the potential to reduce the adverse health effects of smoking and ultimately the risk of smoking-related diseases. Switching to mTHS for 90 days led to reductions in a number of biomarkers of exposure in smokers, relative to those who continued smoking cigarettes, which were close to those observed when stopping smoking (reported in our co-publication, Part 1). Initial findings suggest reduced levels of 8-epi-prostaglandin F2α and intercellular adhesion molecule 1, when switching to mTHS for 90 days. These changes a |
| doi_str_mv | 10.1093/ntr/ntz084 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7164580</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><oup_id>10.1093/ntr/ntz084</oup_id><sourcerecordid>2232119758</sourcerecordid><originalsourceid>FETCH-LOGICAL-c408t-9dfd093fe499b70eb9cad0c13cb76bf0f2012a8339f5d4bfd9c21585dd0dcac53</originalsourceid><addsrcrecordid>eNp9kcFO3DAQQKOqVaHQSz-gmkslWinUdpJNfEGiK-hWAhWxVOrNcuzxJiWJt7azCD6s31eHBUQvPVi2PG_ejGaS5B0lh5Tw7PMQXDx3pMpfJLs0n_GU8_zny_s3Sxkj2U7yxvtfhDBKK_o62ckoZQUp-W7y51RurJN1hzBv5LBCD-0AX1rbS3eNzoM1cGEDDqGVHSyk6yFYuEQ9KoTQIBzrTcQQFii70MCJMajCfdqyt9ftsJp803OSLW_aoJrpM0qm7PMobmwHV7aWStnJEqbw8tYH7IEdMjDWQQbnNoIeDi6kC8A-7ievjOw8vn2495IfpydX80V69v3rt_nxWapyUoWUa6PjhAzmnNclwZorqYmimarLWW2IYYQyWWUZN4XOa6O5YrSoCq2JVlIV2V5ytPWux7pHrWK7TnZi7do4n1thZSv-jQxtI1Z2I0o6y4uKRMHBg8DZ3yP6IPrWK-w6OaAdvWAsi0vhZVFF9NMWVc5679A8laFETIsWsYTYLjrC75839oQ-bjYCH7aAHdf_E_0FBmO1EA</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2232119758</pqid></control><display><type>article</type><title>Favorable Changes in Biomarkers of Potential Harm to Reduce the Adverse Health Effects of Smoking in Smokers Switching to the Menthol Tobacco Heating System 2.2 for 3 Months (Part 2)</title><source>Oxford University Press Journals</source><source>Alma/SFX Local Collection</source><creator>Haziza, Christelle ; de La Bourdonnaye, Guillaume ; Donelli, Andrea ; Skiada, Dimitra ; Poux, Valerie ; Weitkunat, Rolf ; Baker, Gizelle ; Picavet, Patrick ; Lüdicke, Frank</creator><creatorcontrib>Haziza, Christelle ; de La Bourdonnaye, Guillaume ; Donelli, Andrea ; Skiada, Dimitra ; Poux, Valerie ; Weitkunat, Rolf ; Baker, Gizelle ; Picavet, Patrick ; Lüdicke, Frank</creatorcontrib><description>Abstract
Introduction
Tobacco Heating System (THS) 2.2, a candidate modified-risk tobacco product, aims at offering an alternative to cigarettes for smokers while substantially reducing the exposure to harmful and potentially harmful constituents found in cigarette smoke.
Methods
One hundred and sixty healthy adult US smokers participated in this randomized, three-arm parallel group, controlled clinical study. Subjects were randomized in a 2:1:1 ratio to menthol Tobacco Heating System 2.2 (mTHS), menthol cigarette, or smoking abstinence for 5 days in confinement and 86 subsequent ambulatory days. Endpoints included biomarkers of exposure to harmful and potentially harmful constituents (reported in our co-publication, Part 1) and biomarkers of potential harm (BOPH).
Results
Compliance (protocol and allocated product exposure) was 51% and 18% in the mTHS and smoking abstinence arms, respectively, on day 90. Nonetheless, favorable changes in BOPHs of lipid metabolism (total cholesterol and high- and low-density cholesterol), endothelial dysfunction (soluble intercellular adhesion molecule-1), oxidative stress (8-epi-prostaglandin F2α), and cardiovascular risk factors (eg, high-sensitivity C-reactive protein) were observed in the mTHS group. Favorable effects in other BOPHs, including ones related to platelet activation (11-dehydrothromboxane B2) and metabolic syndrome (glucose), were more pronounced in normal weight subjects.
Conclusions
The results suggest that the reduced exposure demonstrated when switching to mTHS is associated with overall improvements in BOPHs, which are indicative of pathomechanistic pathways underlying the development of smoking-related diseases, with some stronger effects in normal weight subjects.
Implications
Switching to mTHS was associated with favorable changes for some BOPHs indicative of biological pathway alterations (eg, oxidative stress and endothelial dysfunction). The results suggest that switching to mTHS has the potential to reduce the adverse health effects of smoking and ultimately the risk of smoking-related diseases. Switching to mTHS for 90 days led to reductions in a number of biomarkers of exposure in smokers, relative to those who continued smoking cigarettes, which were close to those observed when stopping smoking (reported in our co-publication, Part 1). Initial findings suggest reduced levels of 8-epi-prostaglandin F2α and intercellular adhesion molecule 1, when switching to mTHS for 90 days. These changes are comparable to what is observed upon smoking cessation. In normal weight subjects, additional favorable changes were seen in 11-dehydrothromboxane B2, fibrinogen, homocysteine, hs-CRP, percentage of predicted forced expiratory volume in 1 second, systolic blood pressure, diastolic blood pressure, glucose, high-density lipoprotein, apolipoprotein A1, and triglycerides.
Trial registration
NCT01989156.</description><identifier>ISSN: 1462-2203</identifier><identifier>EISSN: 1469-994X</identifier><identifier>DOI: 10.1093/ntr/ntz084</identifier><identifier>PMID: 31125079</identifier><language>eng</language><publisher>US: Oxford University Press</publisher><subject>Original Investigations</subject><ispartof>Nicotine & tobacco research, 2020-04, Vol.22 (4), p.549-559</ispartof><rights>The Author(s) 2019. Published by Oxford University Press on behalf of the Society for Research on Nicotine and Tobacco. 2019</rights><rights>The Author(s) 2019. Published by Oxford University Press on behalf of the Society for Research on Nicotine and Tobacco.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c408t-9dfd093fe499b70eb9cad0c13cb76bf0f2012a8339f5d4bfd9c21585dd0dcac53</citedby><cites>FETCH-LOGICAL-c408t-9dfd093fe499b70eb9cad0c13cb76bf0f2012a8339f5d4bfd9c21585dd0dcac53</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,776,780,881,1578,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/31125079$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Haziza, Christelle</creatorcontrib><creatorcontrib>de La Bourdonnaye, Guillaume</creatorcontrib><creatorcontrib>Donelli, Andrea</creatorcontrib><creatorcontrib>Skiada, Dimitra</creatorcontrib><creatorcontrib>Poux, Valerie</creatorcontrib><creatorcontrib>Weitkunat, Rolf</creatorcontrib><creatorcontrib>Baker, Gizelle</creatorcontrib><creatorcontrib>Picavet, Patrick</creatorcontrib><creatorcontrib>Lüdicke, Frank</creatorcontrib><title>Favorable Changes in Biomarkers of Potential Harm to Reduce the Adverse Health Effects of Smoking in Smokers Switching to the Menthol Tobacco Heating System 2.2 for 3 Months (Part 2)</title><title>Nicotine & tobacco research</title><addtitle>Nicotine Tob Res</addtitle><description>Abstract
Introduction
Tobacco Heating System (THS) 2.2, a candidate modified-risk tobacco product, aims at offering an alternative to cigarettes for smokers while substantially reducing the exposure to harmful and potentially harmful constituents found in cigarette smoke.
Methods
One hundred and sixty healthy adult US smokers participated in this randomized, three-arm parallel group, controlled clinical study. Subjects were randomized in a 2:1:1 ratio to menthol Tobacco Heating System 2.2 (mTHS), menthol cigarette, or smoking abstinence for 5 days in confinement and 86 subsequent ambulatory days. Endpoints included biomarkers of exposure to harmful and potentially harmful constituents (reported in our co-publication, Part 1) and biomarkers of potential harm (BOPH).
Results
Compliance (protocol and allocated product exposure) was 51% and 18% in the mTHS and smoking abstinence arms, respectively, on day 90. Nonetheless, favorable changes in BOPHs of lipid metabolism (total cholesterol and high- and low-density cholesterol), endothelial dysfunction (soluble intercellular adhesion molecule-1), oxidative stress (8-epi-prostaglandin F2α), and cardiovascular risk factors (eg, high-sensitivity C-reactive protein) were observed in the mTHS group. Favorable effects in other BOPHs, including ones related to platelet activation (11-dehydrothromboxane B2) and metabolic syndrome (glucose), were more pronounced in normal weight subjects.
Conclusions
The results suggest that the reduced exposure demonstrated when switching to mTHS is associated with overall improvements in BOPHs, which are indicative of pathomechanistic pathways underlying the development of smoking-related diseases, with some stronger effects in normal weight subjects.
Implications
Switching to mTHS was associated with favorable changes for some BOPHs indicative of biological pathway alterations (eg, oxidative stress and endothelial dysfunction). The results suggest that switching to mTHS has the potential to reduce the adverse health effects of smoking and ultimately the risk of smoking-related diseases. Switching to mTHS for 90 days led to reductions in a number of biomarkers of exposure in smokers, relative to those who continued smoking cigarettes, which were close to those observed when stopping smoking (reported in our co-publication, Part 1). Initial findings suggest reduced levels of 8-epi-prostaglandin F2α and intercellular adhesion molecule 1, when switching to mTHS for 90 days. These changes are comparable to what is observed upon smoking cessation. In normal weight subjects, additional favorable changes were seen in 11-dehydrothromboxane B2, fibrinogen, homocysteine, hs-CRP, percentage of predicted forced expiratory volume in 1 second, systolic blood pressure, diastolic blood pressure, glucose, high-density lipoprotein, apolipoprotein A1, and triglycerides.
Trial registration
NCT01989156.</description><subject>Original Investigations</subject><issn>1462-2203</issn><issn>1469-994X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>TOX</sourceid><recordid>eNp9kcFO3DAQQKOqVaHQSz-gmkslWinUdpJNfEGiK-hWAhWxVOrNcuzxJiWJt7azCD6s31eHBUQvPVi2PG_ejGaS5B0lh5Tw7PMQXDx3pMpfJLs0n_GU8_zny_s3Sxkj2U7yxvtfhDBKK_o62ckoZQUp-W7y51RurJN1hzBv5LBCD-0AX1rbS3eNzoM1cGEDDqGVHSyk6yFYuEQ9KoTQIBzrTcQQFii70MCJMajCfdqyt9ftsJp803OSLW_aoJrpM0qm7PMobmwHV7aWStnJEqbw8tYH7IEdMjDWQQbnNoIeDi6kC8A-7ievjOw8vn2495IfpydX80V69v3rt_nxWapyUoWUa6PjhAzmnNclwZorqYmimarLWW2IYYQyWWUZN4XOa6O5YrSoCq2JVlIV2V5ytPWux7pHrWK7TnZi7do4n1thZSv-jQxtI1Z2I0o6y4uKRMHBg8DZ3yP6IPrWK-w6OaAdvWAsi0vhZVFF9NMWVc5679A8laFETIsWsYTYLjrC75839oQ-bjYCH7aAHdf_E_0FBmO1EA</recordid><startdate>20200417</startdate><enddate>20200417</enddate><creator>Haziza, Christelle</creator><creator>de La Bourdonnaye, Guillaume</creator><creator>Donelli, Andrea</creator><creator>Skiada, Dimitra</creator><creator>Poux, Valerie</creator><creator>Weitkunat, Rolf</creator><creator>Baker, Gizelle</creator><creator>Picavet, Patrick</creator><creator>Lüdicke, Frank</creator><general>Oxford University Press</general><scope>TOX</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20200417</creationdate><title>Favorable Changes in Biomarkers of Potential Harm to Reduce the Adverse Health Effects of Smoking in Smokers Switching to the Menthol Tobacco Heating System 2.2 for 3 Months (Part 2)</title><author>Haziza, Christelle ; de La Bourdonnaye, Guillaume ; Donelli, Andrea ; Skiada, Dimitra ; Poux, Valerie ; Weitkunat, Rolf ; Baker, Gizelle ; Picavet, Patrick ; Lüdicke, Frank</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c408t-9dfd093fe499b70eb9cad0c13cb76bf0f2012a8339f5d4bfd9c21585dd0dcac53</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Original Investigations</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Haziza, Christelle</creatorcontrib><creatorcontrib>de La Bourdonnaye, Guillaume</creatorcontrib><creatorcontrib>Donelli, Andrea</creatorcontrib><creatorcontrib>Skiada, Dimitra</creatorcontrib><creatorcontrib>Poux, Valerie</creatorcontrib><creatorcontrib>Weitkunat, Rolf</creatorcontrib><creatorcontrib>Baker, Gizelle</creatorcontrib><creatorcontrib>Picavet, Patrick</creatorcontrib><creatorcontrib>Lüdicke, Frank</creatorcontrib><collection>Oxford University Press Open Access</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Nicotine & tobacco research</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Haziza, Christelle</au><au>de La Bourdonnaye, Guillaume</au><au>Donelli, Andrea</au><au>Skiada, Dimitra</au><au>Poux, Valerie</au><au>Weitkunat, Rolf</au><au>Baker, Gizelle</au><au>Picavet, Patrick</au><au>Lüdicke, Frank</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Favorable Changes in Biomarkers of Potential Harm to Reduce the Adverse Health Effects of Smoking in Smokers Switching to the Menthol Tobacco Heating System 2.2 for 3 Months (Part 2)</atitle><jtitle>Nicotine & tobacco research</jtitle><addtitle>Nicotine Tob Res</addtitle><date>2020-04-17</date><risdate>2020</risdate><volume>22</volume><issue>4</issue><spage>549</spage><epage>559</epage><pages>549-559</pages><issn>1462-2203</issn><eissn>1469-994X</eissn><abstract>Abstract
Introduction
Tobacco Heating System (THS) 2.2, a candidate modified-risk tobacco product, aims at offering an alternative to cigarettes for smokers while substantially reducing the exposure to harmful and potentially harmful constituents found in cigarette smoke.
Methods
One hundred and sixty healthy adult US smokers participated in this randomized, three-arm parallel group, controlled clinical study. Subjects were randomized in a 2:1:1 ratio to menthol Tobacco Heating System 2.2 (mTHS), menthol cigarette, or smoking abstinence for 5 days in confinement and 86 subsequent ambulatory days. Endpoints included biomarkers of exposure to harmful and potentially harmful constituents (reported in our co-publication, Part 1) and biomarkers of potential harm (BOPH).
Results
Compliance (protocol and allocated product exposure) was 51% and 18% in the mTHS and smoking abstinence arms, respectively, on day 90. Nonetheless, favorable changes in BOPHs of lipid metabolism (total cholesterol and high- and low-density cholesterol), endothelial dysfunction (soluble intercellular adhesion molecule-1), oxidative stress (8-epi-prostaglandin F2α), and cardiovascular risk factors (eg, high-sensitivity C-reactive protein) were observed in the mTHS group. Favorable effects in other BOPHs, including ones related to platelet activation (11-dehydrothromboxane B2) and metabolic syndrome (glucose), were more pronounced in normal weight subjects.
Conclusions
The results suggest that the reduced exposure demonstrated when switching to mTHS is associated with overall improvements in BOPHs, which are indicative of pathomechanistic pathways underlying the development of smoking-related diseases, with some stronger effects in normal weight subjects.
Implications
Switching to mTHS was associated with favorable changes for some BOPHs indicative of biological pathway alterations (eg, oxidative stress and endothelial dysfunction). The results suggest that switching to mTHS has the potential to reduce the adverse health effects of smoking and ultimately the risk of smoking-related diseases. Switching to mTHS for 90 days led to reductions in a number of biomarkers of exposure in smokers, relative to those who continued smoking cigarettes, which were close to those observed when stopping smoking (reported in our co-publication, Part 1). Initial findings suggest reduced levels of 8-epi-prostaglandin F2α and intercellular adhesion molecule 1, when switching to mTHS for 90 days. These changes are comparable to what is observed upon smoking cessation. In normal weight subjects, additional favorable changes were seen in 11-dehydrothromboxane B2, fibrinogen, homocysteine, hs-CRP, percentage of predicted forced expiratory volume in 1 second, systolic blood pressure, diastolic blood pressure, glucose, high-density lipoprotein, apolipoprotein A1, and triglycerides.
Trial registration
NCT01989156.</abstract><cop>US</cop><pub>Oxford University Press</pub><pmid>31125079</pmid><doi>10.1093/ntr/ntz084</doi><tpages>11</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1462-2203 |
| ispartof | Nicotine & tobacco research, 2020-04, Vol.22 (4), p.549-559 |
| issn | 1462-2203 1469-994X |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7164580 |
| source | Oxford University Press Journals; Alma/SFX Local Collection |
| subjects | Original Investigations |
| title | Favorable Changes in Biomarkers of Potential Harm to Reduce the Adverse Health Effects of Smoking in Smokers Switching to the Menthol Tobacco Heating System 2.2 for 3 Months (Part 2) |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-11T20%3A30%3A58IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Favorable%20Changes%20in%20Biomarkers%20of%20Potential%20Harm%20to%20Reduce%20the%20Adverse%20Health%20Effects%20of%20Smoking%20in%20Smokers%20Switching%20to%20the%20Menthol%20Tobacco%20Heating%20System%202.2%20for%203%20Months%20(Part%202)&rft.jtitle=Nicotine%20&%20tobacco%20research&rft.au=Haziza,%20Christelle&rft.date=2020-04-17&rft.volume=22&rft.issue=4&rft.spage=549&rft.epage=559&rft.pages=549-559&rft.issn=1462-2203&rft.eissn=1469-994X&rft_id=info:doi/10.1093/ntr/ntz084&rft_dat=%3Cproquest_pubme%3E2232119758%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2232119758&rft_id=info:pmid/31125079&rft_oup_id=10.1093/ntr/ntz084&rfr_iscdi=true |